Theralase Technologies (CVE:TLT) Sets New 52-Week Low at $0.15

Theralase Technologies Inc. (CVE:TLTGet Free Report) reached a new 52-week low on Friday . The company traded as low as C$0.15 and last traded at C$0.16, with a volume of 310600 shares traded. The stock had previously closed at C$0.16.

Theralase Technologies Price Performance

The stock has a 50 day simple moving average of C$0.17 and a two-hundred day simple moving average of C$0.18. The company has a market cap of C$38.29 million, a price-to-earnings ratio of -8.00 and a beta of 1.59. The company has a debt-to-equity ratio of 20.30, a current ratio of 1.39 and a quick ratio of 3.40.

Theralase Technologies (CVE:TLTGet Free Report) last released its quarterly earnings data on Wednesday, March 27th. The company reported C($0.01) earnings per share for the quarter. The business had revenue of C$0.36 million during the quarter. On average, equities research analysts predict that Theralase Technologies Inc. will post -0.05 earnings per share for the current fiscal year.

Theralase Technologies Company Profile

(Get Free Report)

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.

Further Reading

Receive News & Ratings for Theralase Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theralase Technologies and related companies with MarketBeat.com's FREE daily email newsletter.